Levels of Circulating T Cells Expressing VLA-1 Collagen Receptors - Full Text View

Sponsored by:	Sheba Medical Center
Information provided by:	Sheba Medical Center
ClinicalTrials.gov Identifier:	NCT00708838

Purpose

The examination of the percentage of peripheral T cells carrying VLA-1 in ischemic heart disease patients. The hypothesis is that the percentage levels of cells carrying this integrin rise according to the severity of the ischemic heart disease.

Condition
Ischemic Heart Disease

MedlinePlus related topics: Heart Diseases

U.S. FDA Resources

Study Type:	Observational
Study Design:	Case-Only, Prospective
Official Title:	VLA-1 Receptors on Peripheral T Cells in Ischemic Heart Disease Patients

Further study details as provided by Sheba Medical Center:

Primary Outcome Measures:

The differance in percentage of T cells in the 5 different groups involved. [ Time Frame: 2002-2006 ] [ Designated as safety issue: No ]

Biospecimen Retention: None Retained

Biospecimen Description:

Blood samples isolated from patients included in the study and anallysed by FACS

Enrollment:	151
Study Start Date:	January 2002
Study Completion Date:	February 2007
Primary Completion Date:	January 2006 (Final data collection date for primary outcome measure)

Groups/Cohorts
1
2
3
4
5

Detailed Description:

Atherosclerosis is considered an inflammatory disease in which lymphocytes have an important role. The study was disigned to find out the changes in T cell levels carrying VLA-1 involvement in this process.

Eligibility

Ages Eligible for Study:	18 Years to 80 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Probability Sample

Criteria

Inclusion Criteria:

clinical diagnosis of acute MI for group 1
clinical diagnosis of ACSl for group 2
clinical diagnosis of Chronic Heart Disease for groups 3 and 4
Chest pain but normal heart scan for group 5

Exclusion Criteria:

none

Contacts and Locations

No Contacts or Locations Provided

More Information

Responsible Party:	Sheba Medical Center, Heart Institute ( Arik Asman )
Study ID Numbers:	SHEBA-02-2707-AA-CTIL
Study First Received:	July 1, 2008
Last Updated:	July 1, 2008
ClinicalTrials.gov Identifier:	NCT00708838
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Study placed in the following topic categories:

Heart Diseases
Myocardial Ischemia
Vascular Diseases
Ischemia

Additional relevant MeSH terms:

Cardiovascular Diseases

ClinicalTrials.gov processed this record on January 14, 2009